L-DOPA increases noradrenaline turnover in central and peripheral nervous systems

Neuropharmacology

Volumn 45, Issue 4, 2003, Pages 524-533

  Dayan, Lior ^a   Finberg, John P M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

L DOPA; MAO; Microdialysis; Noradrenaline; Rasagiline; Vas deferens

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CLORGYLINE; DESIPRAMINE; DOPAMINE; GLYCOL; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N METHYL N (2 PROPYNYL) 1 INDANAMINE; NORADRENALIN; RASAGILINE; SODIUM ION; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AXOPLASM; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ELECTROSTIMULATION; FRONTAL CORTEX; HYPOTHESIS; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN RELEASE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; SODIUM TRANSPORT; SYMPATHETIC INNERVATION; VAS DEFERENS;

EID: 0041696476     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00190-4     Document Type: Article

References (35)

1. Amobi N.I.B., Smith I.C.H. Adrenergic modulation of "non-adrenergic" twitches in the rat vas deferens. Journal of Autonomic Pharmacology. 8:1988;141-152.
2. Brannan T., Prikhojan A., Yahr M.D. An in vivo comparison of the capacity of striatal versus extrastriatal regions to form dopamine from exogenously administered L-dopa. Journal of Neural Transmission. 103:1996;1287-1294.
3. Brown D.A., Docherty J.R., French A.M., MacDonald A., McGrath J.C., Scott N.C. Separation of adrenergic and non-adrenergic contractions to field stimulation in the rat vas deferens. British Journal of Pharmacology. 79:1983;379-393.
4. Bulloch J.M., McGrath J.C. Blockade of vasopressor and vas deferens responses by alpha, beta-methylene ATP in the pithed rat. British Journal of Pharmacology. 94:1988;103-108.
5. Dayan L., Finberg J.P.M. L-DOPA increases intraneuronal release of noradrenaline in rat frontal cortex. British Journal of Pharmacology. 136:2002;1-85.
6. Dolphin A., Jenner P., Marsden C.P. Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. Pharmacology Biochemistry and Behaviour. 5:1976;431-439.
7. Edwards D.J., Rizk M. Conversion of 3, 4-dihydroxyphenylalanine and deuterated 3, 4-dihydroxyphenylalanine to alcoholic metabolites of catecholamines in rat brain. Journal of Neurochemistry. 36:1981;1641-1647.
8. Eisenhofer G., Ropchak T.G., Stull R.W., Goldstein D.S., Keiser H.R., Kopin I.J. Dihydroxyphenylglycol and intraneuronal metabolism of endogenous and exogenous norepinephrine in the rat vas deferens. Journal of Pharmacology and Experimental Therapeutics. 241:1987;547-553.
9. Farmer J.B. Indirect sympathomimetic actions of dopamine. Journal of Pharmacy and Pharmacology. 18:1966;261-262.
10. Fillenz M., Stanford S.C. Vesicular noradrenaline stores in peripheral nerves of the rat and their modification by tranylcypromine. British Journal of Pharmacology. 73:1981;401-404.
11. Finberg J.P.M., Tenne M., Youdim M.B.H. Tyramine antagonistic properties of AGN 1135 - an irreversible inhibitor of monoamine oxidase type B. British Journal of Pharmacology. 73:1981;65-74.
12. Finberg J.P.M., Pacak K., Kopin I.J., Goldstein D.S. Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex. Naunyn-Schmiedeberg's Arch Pharmacol. 347:1993;500-505.
13. Forno L.S. Neuropathology of Parkinson's disease. Journal of Neuropathology and Experimental Neurology. 55:1996;259-272.
14. Gesi M., Soldani P., Giorgi F.S., Santinami A., Bonaccorsi I., Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neuroscience and Biobehaviour Reviews. 24:2000;655-668.
15. Gomez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clinical Neuropharmacology. 16:1993;418-427.
16. Goshima Y., Nakamura S., Ohno K., Misu Y. Picomolar concentrations of L-DOPA stereoselectively potentiate activities of presynaptic beta-adrenoceptors to facilitate the release of endogenous noradrenaline from rat hypothalamic slices. Neuroscience Letters. 129:1991;214-216.
17. Grondin R., Hadj Tahar A., Doan V.D., Ladure P., Bedard P.J. Noradrenoceptor antagonism with idazoxan improves L-DOPA-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg's Archives of Pharmacology. 361:2000;181-186.
18. Hornykiewicz O., Kish S.J. Biochemical pathophysiology in Parkinson's disease. Advances in Neurology. 45:1987;19-34.
19. Hornykiewicz O., Pifl C. The validity of the MPTP primate model for neurochemical pathology of idiopathic Parkinson's disease. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;59-71 CRC Press, Boca Raton.
20. Jarrott B., Iversen L.L. Noradrenaline metabolizing enzymes in normal and sympethetically-denervated rat vas deferens. Journal of Neurochemistry. 18:1971;1-6.
21. Jonsson G., Hallman H., Ponzio F., Ross S. DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine); a useful denervation tool for central and peripheral noradrenaline neurons. European Journal of Pharmacology. 72:1981;173-188.
22. Landa M.E., Rubio M.C., Jaim-Etcheverry G. The aziridinium derivative of DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) accelerates the beating rate of isolated rat atria by enhancing the spontaneous release of noradrenaline. Naunyn-Schmiedebergs Archives of Pharmacology. 336:1987;396-402.
23. Lategan A.J., Marien M.R., Colpaert F.C. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Research. 523:1990;134-138.
24. Mann D.M.A., Yates P.O., Hawkws J. The pathology of the human locus ceruleus. Clinical Neuropathology. 2:1983;1-7.
25. Mayeux R. Depression in the patient with Parkinson's disease. Journal of Clinical Psychiatry. 51:1990;20-23.
26. McGrath J.C. Adrenergic and "non-adrenergic" components in the contractile response of the vas deferens to a single indirect stimulation. Journal of Physiology. 283:1978;23-39.
27. Melamed E., Hefti F., Wurtman R.J. Nonaminergic striatal neurons convert exogenous L-DOPA to dopamine in Parkinsonism. Ann Neurol. 8:1980;558-563.
28. Misu Y., Goshima Y., Ueda H., Okamura H. Neurobiology of L-DOPAergic systems. Progress in Neurobiology. 49:1996;415-454.
29. Nakamura S., Goshima Y., Yue J.L., Misu Y. Transmitter-like basal and K+-evoked release of 3,4-dihydroxyphenylalanine from the striatum in conscious rats studied by microdialysis. Journal of Neurochemistry. 58:1992;270-275.
30. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research. 275:1983;321-328.
31. Sneddon P., Machaly M. Regional variation in purinergic and adrenergic responses in isolated vas deferens of rat, rabbit and guinea pig. Journal of Autonomic Pharmacology. 12:1992;421-428.
32. Trendelenburg U.H., Bonisch H., Graefe K.-H., Henseling M. The rate constants for the efflux of metabolites of catecholamines and phenethylamines. Pharmacology Reviews. 31:1979;179-203.
33. Witt P.A., Kramer T.H., Burks T.F. Norepinephrine and ATP are synergistic in the mouse vas deferens preparation. European Journal of Pharmacology. 204:1991;149-155.
34. Youdim M.B.H., Finberg J.P.M., Tipton K.F. Monoamine oxidase. Trendelenburg U., Weiner N. Catecholamines. vol. 1:1988;119-192 Springer, Berlin, Heidelberg, New York.
35. Youdim M.B.H., Gross A., Finberg J.P.M. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British Journal of Pharmacology. 132:2001;500-506.